Mechanism of differential effects of antihypertensive agents on serum lipids

Current Hypertension Reports

Volumn 2, Issue 4, 2000, Pages 370-377

  Brook, Robert D ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZOTHIADIAZINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; INSULIN; LIPID; LIPOPROTEIN; THIAZIDE DIURETIC AGENT;

AUTONOMIC NERVOUS SYSTEM; BLOOD; DRUG EFFECT; HUMAN; METABOLISM; MICROCIRCULATION; POSTPRANDIAL STATE; REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; AUTONOMIC NERVOUS SYSTEM; BENZOTHIADIAZINES; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; INSULIN; LIPIDS; LIPOPROTEINS; MICROCIRCULATION; POSTPRANDIAL PERIOD; SODIUM CHLORIDE SYMPORTER INHIBITORS;

EID: 0034243129     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-000-0040-0     Document Type: Article

References (50)

1. Collins R, Peto R, MacMahon S, et al.: Blood pressure, stroke, and coronary artery disease. Part 2. Short-term reduction in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990, 335: 827-838.
2. Julius S, Jamerson K: Sympathetics, insulin resistance and coronary risk in hypertension: the chicken and egg' question. J Hypertens 1994, 12: 495-502.
3. Hansson L, Lindholm LH, Ekbom T, et al.: Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension 2 study. Lancet 1999, 354: 1751-1756. Recent study demonstrated that the new antihypertensive medications provide the same cardiovascular risk protection as the old agents in elderly patients with hypertension. ACE inhibitors and calcium channel blockers were not found to be superior to diuretics.
4. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin converting enzyme inhibition compared with conven tional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353: 611-616
5. Kasiske BL, Ma JZ, Roberto SN, et al.: Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995, 122: 133-141.
6. Lakshman MR, Reda DJ, Matersib BJ, et al.: Diuretics and beta blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Arch Intern Med 1999, 159: 551-558. Analysis of the Veteran's trial that demonstrates that (3-blockers and diuretics cause very few metabolic abnormalities with prolonged use.
7. Savage PJ, Pressel SL, Curb JD, et al.: Influence of long-term, low dose, diuretic based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: The Systolic Hypertension in the Elderly Program. Arch Intern Med 1998, 158: 741-751. Analysis of data from the Systolic Hypertension in the Elderly trial demonstrates that low-dose diuretic therapy is associated with minimal lipid alterations.
8. Grimm RH, Flack JM, Grandits GA, et al.: Long-term effects on plasma lipids of diet and drugs to treat hypertension. JAMA 1996, 275: 1549-1556.
9. Groop L, Bodadonna RC, DelPrato S, et al.: Effect of insulin on oxidative and non oxidative pathways of glucose and FFA metabolism in NIDDM. J Clin Invest 1989, 84: 205-213.
10. Nurjhan N, Consoli A, Gerich J: Increased lipolysis and its consequences on gluconeogenesis in non insulin dependent diabetes mellitus. J Clin Invest 1992, 89: 169-175.
11. Byrne CD, Wareham NJ, Brown DC, et al.: Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non esterified fatty acids. Diabetologia 1994, 37: 889-896.
12. Lewis GF, Uffelman KD, Szeto LW, et al.: Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 1995, 95: 158-166.
13. Koopmans SJ, Kushwaha RS, DeFronzo RA: Chronic physiologic hyperinsulinemia impairs suppression of plasma free fatty acids and increases de novo lipogenesis but does not cause dyslipidemia in conscious normal rats. Metabolism 1999, 48: 330-337.
14. Pollare T, Vessby B, Lithell H: Lipoprotein lipase activity in skeletal muscle is related to insulin sensitivity. Arterioscler Thromb 1991, 11: 1124-1129.
15. Taylor KG, Galton DJ, Holdsworth G: Insulin-independent diabetes: a defect in the activity of lipoprotein lipase in adipocyte tissue. Diabetologia 1979, 16: 313-317.
16. Summers LKM, Samra JS, Frayn K: Impaired postprandial tissue regulation of blood flow in insulin resistance: a deter minant of cardiovascular risk? Atherosclerosis 1999, 147: 11-15.
17. Sniderman AD, Cianflone K, Arner P, et al.: The adipocyte, fatty acid trapping, and atherogenesis. Arterioscler Thromb Vasc Biol 1998, 18: 147-151.
18. Julius S, Gudbrandsson T, Jamerson K: The hemodynamic link between insulin resistance and hypertension. J Hypertension 1991, 9: 983-986.
19. Mackintosh VS, Elsegood CL, Redgrave TG: Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats. Clin Exp PharmacolPhysiol 1991, 18: 775-788.
20. Superko HR, Haskell WL, Krauss RM: Association of lipoprotein subclass distribution with use of selective and nonselective beta-blocker medications in patients with coronary artery disease. Arteriosclerosis 1993, 101: 1-8.
21. Pedersen SB, Bak JF, Holck P, et al.: Epinephrine stimulates human muscle lipoprotein lipase activity in vivo. Metabolism 1999, 48: 461-464.
22. Anavekar SN, Jarrott B, Toscano M, et al.: Pharmacokinetic and pharmacodynamic studies of oral clonidine in normotensive subjects. Eur J Clin Pharmacol 1986, 112: 900-906.
23. Ames RP: Hyperlipidemia in hypertension: causes and prevention. Am Heart J 1991, 122: 1219-1224.
24. Weidmann P, De Courten M, Ferrari P: Effect of diuretics on the plasma lipid profile. Eur Heart J 1992, 13(suppl G):61-67.
25. Rossner S, Taylor Cl, Byington RP, et al.: Long term propranolol treatment and changes in body weight after myocardial infarction. Br Med J 1990, 300: 902-903.
26. Lithell H: Hypertension and hyperlipidemia. Am J Hypertens 1993, 6: 303S-308S.
27. Reavan G: Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37: 1595-1607.
28. Jacob S, Rett K, Henriksen EJ: Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998, 11: 1258-1265.
29. Pollare T, Lithell HO, Selinus I, et al.: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989, 298: 1152-1157.
30. Lind L, Lithell H: Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 1993, 125: 1494-1497.
31. Lithell H, Pollare T, Berne C, et al.: The metabolic and circulatory response to beta-blockade in hypertensive men is correlated to muscle capillary density. Blood Pressure 1992, 1: 20-26.
32. DeFronzo RA, Thorin D, Felber J P, et al.: Effect of beta and alpha adrenergic blockade on glucose-induced thermogenesis. J Clin Invest 1984, 73: 633-639.
33. Toft I, Bonaa KH, Jenssen T: Insulin resistance in hypertension is associated with body fat rather than blood pressure. Hypertension 1998, 32: 115-122.
34. Patsch JR, Miesenbock G, Hopferwieser T, et al.: Relation of triglyceride metabolism and coronary artery disease. Aterioscler Thromb 1992, 12: 1336-1345.
35. Boquist S, Ruotolo G, Hellenius ML, et al.: Effects of a cardi oselective 3 blocker on postprandial triglyceride rich lipoproteins, low density lipoprotein particle size and glucose insulin homeostasis in middle aged men with modestly increased cardiovascular risk. Atherosclerosis 1998, 137: 391-400. Study that demonstrates that (3-blockers enhance postprandial lipemia and cause a shift in the size of LDL toward a smaller, denser particle that is more highly atherogenic.
36. Haenni A, Lithell H: Treatment with a 3 blocker that has 32 agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994, 43: 455-461.
37. Tikkanen HO, Naveri H, Harkonen M: Skeletal muscle fiber distribution influences serum high density lipoprotein cholesterol level. Atherosclerosis 1996, 120: 1-5.
38. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double blind cross over study in hypertensive patients. Blood Pressure 1992, 1: 92-101.
39. Day Jl, Metcalfe J, Simpson CN: Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 1982, 284: 1145-1148.
40. Campos H, Genest JJ, Blijlevens E, et al.: Low density lipoprotein particle size and coronary artery disease. Arterioscler Thromb 1992, 12: 187-195.
41. Lamarch B, Tchernof A, Moorjani S, et al.: Small, dense lowdensity lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997, 95: 69-75.
42. Weidmann P, De Courten M, Ferrari P: Effect of diuretics on the plasma lipid profile. Eur Heart J 1992, 13(suppl G):61-67.
43. Helderman JH, Klahi D, Amdersem DK, et al.: Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1932, 32: 106-111.
44. Ames RP: Hyperlipidemia in hypertension: causes and prevention. Am Heart J 1991, 122: 1219-1224.
45. Andersson P, Lithell H: Metabolic effects of doxazosin and enalaril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. Am J Hypertens 1996, 9: 323-333.
46. Boquist S, Ruotolo G, Tang R, et al.: Alimentary lipemia, postprandial triglyceride rich lipoproteins, and common carotid intima media thickness in healthy, middle aged men. Circulation 1999, 100: 723-728.
47. Vogel R, Corretti MC, Plotnick GD: Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol 1997, 79: 350-354.
48. Doi H, Kugiyama K, Ohgushi M, et al.: Membrane active lipids in remnant lipoproteins cause impairment of endothelium dependent vasorelaxation. Arterioscler Thromb Vasc Biol 1999, 19: 1918-1924.
49. Kugiyama K, Doi H, Motoyama T, et al.: Association of remnant lipoprotein levels with impairment of endothelium dependent vasomotor function in human coronary arteries. Circulation 1998, 97: 2519-2526.
50. Wilmink H, Banga JD, Hijmering M, et al.: Effect of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor antagonism on postprandial endothelial function. J Am Coll Cardiol 1999, 34: 140-145. Study that demonstrates that both ACE inhibitor and angiotensin receptor blocker therapy can prevent or reduce the degree of postprandial endothelial dysfunction that occurs after eating a high-fat meal.